GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » China Health Group Inc (FRA:VNL1) » Definitions » EV-to-EBIT

China Health Group (FRA:VNL1) EV-to-EBIT : -1.06 (As of Jun. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is China Health Group EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, China Health Group's Enterprise Value is €7.89 Mil. China Health Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-7.46 Mil. Therefore, China Health Group's EV-to-EBIT for today is -1.06.

The historical rank and industry rank for China Health Group's EV-to-EBIT or its related term are showing as below:

FRA:VNL1' s EV-to-EBIT Range Over the Past 10 Years
Min: -107.1   Med: 5.05   Max: 2970.53
Current: -1.04

During the past 13 years, the highest EV-to-EBIT of China Health Group was 2970.53. The lowest was -107.10. And the median was 5.05.

FRA:VNL1's EV-to-EBIT is ranked worse than
100% of 100 companies
in the Medical Diagnostics & Research industry
Industry Median: 20.415 vs FRA:VNL1: -1.04

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. China Health Group's Enterprise Value for the quarter that ended in Dec. 2023 was €3.96 Mil. China Health Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-7.46 Mil. China Health Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -188.61%.


China Health Group EV-to-EBIT Historical Data

The historical data trend for China Health Group's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Health Group EV-to-EBIT Chart

China Health Group Annual Data
Trend Dec12 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.60 4.47 6.96 -15.56 -2.02

China Health Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.56 -59.11 -17.09 -14.19 -2.02

Competitive Comparison of China Health Group's EV-to-EBIT

For the Diagnostics & Research subindustry, China Health Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Health Group's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, China Health Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where China Health Group's EV-to-EBIT falls into.



China Health Group EV-to-EBIT Calculation

China Health Group's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=7.890/-7.463
=-1.06

China Health Group's current Enterprise Value is €7.89 Mil.
China Health Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Health Group  (FRA:VNL1) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

China Health Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-7.463/3.95676
=-188.61 %

China Health Group's Enterprise Value for the quarter that ended in Dec. 2023 was €3.96 Mil.
China Health Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Health Group EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of China Health Group's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


China Health Group (FRA:VNL1) Business Description

Traded in Other Exchanges
Address
Building 17, Jianwai SOHO, Chaoyang District, Beijing, CHN
China Health Group Inc is an investment holding company engaged in providing medical care facilities in the People's republic of china. The company provides provision of post launch market research, medical and medical market services (PM services), Provision of contracted pharmaceutical development services (PD services), Provision of contracted clinical research services (CR Services), Drugs technologies, and Other medical services. The majority of the revenue for the company comes from the provision of PM services.

China Health Group (FRA:VNL1) Headlines

No Headlines